Compare Clarify Health vs Zephyr AI
Customers evaluate the quality of Clarify Health's products using the following success metrics.
Overview
Clarify Health is 9 yrs old and is based in United States.
Clarify Health provides an enterprise analytics and payments platform. It delivers end-to-end intelligence on every patient journey, empowering payers, providers, and life sciences companies to make better care decisions. Its platform, Atlas, maps over a million patient journeys, generates over a billion artificial intelligence (AI)-powered predictions, and delivers insights via cloud software applications. The company was founded in 2015 and is based in San Francisco, California.
Zephyr AI is 3 yrs old and is based in United States.
Zephyr AI is a company focused on the development of artificial intelligence solutions in the healthcare and biotechnology sectors. The company's main offerings include the creation of AI tools for precision medicine, drug discovery, and clinical decision support, aiming to improve patient outcomes and reduce healthcare costs. Zephyr AI primarily serves the healthcare industry, partnering with health systems, insurance plans, and biotech pioneers. It was founded in 2021 and is based in Dallas, Texas.
Demo Video
Leadership
Jean Drouin (Founder, Chief Executive Officer)
Yisroel Brumer (Founder)
Funding
Investors
KKR, Aspenwood Ventures
BoxGroup, MedStar Health
Product
Information not available because Clarify Health has not claimed their profile.
Work for Clarify Health? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Clarify Health?
Claim your profile now.
Why Zephyr AI beats Clarify Health
Benefits
- Drug discovery - costs, number of molecules and bio markers discovered, time from discovery to human trials, FDA approvals
- Label expansion- number of indications identified, time to, FDA approved label expansions
- Predictive analytics - patient outcomes, reduction of costs, opportunities for mitigations
Products
"Aura Precision Medicine"
The Aura Precision Medicine Tool uses AI/ML to enable the identification of novel, non-obvious patient populations for approved medications, patient populations likely to have positive outcomes in clinical trials.
Customers
Zephyr AI works with 1 known companies.
Known Partners
NexImmune
Why They Buy
News & Analysis
Clarify Health has been mentioned in our research 8 times.
Zephyr AI has been mentioned in our research 2 times.
Research Articles
Expert Collections
Unicorns- Billion Dollar Startups
1,228 items
Conference Exhibitors
5,501 items
HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare
Digital Health
10,585 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Market
ESP Rankings position vendors based on their resources and execution.
Zephyr AI is a Leader in AI oncology drug development
The AI oncology drug development market leverages artificial intelligence and machine learning techniques to analyze vast amounts of genomic, proteomic, and clinical data, enabling more precise identification of therapeutic targets, prediction of drug responses, and optimization of treatment regimens. AI solutions in oncology drug development help researchers accelerate the discovery of novel compounds, design more effective clinical trials, and improve patient stratification for personalized medicine. By harnessing the power of AI, this market aims to enhance the efficiency and success rate of drug discovery and development, ultimately leading to the delivery of safer, more targeted, and potentially life-saving oncology treatments.